Variables That Are Correlated to Developing Multiple Endocrine Neoplasia (MEN) and Pancreatic Neuroendocrine Tumors (PNET)
Overview
The study aims to identify predictors of disease in patients with hyperparathyroidism (HPTH) who undergo surgery.
Study Type
- Study Type: Observational
- Study Design
- Time Perspective: Retrospective
- Study Primary Completion Date: October 2022
Detailed Description
Researchers aim to identify somatic mutations and inherited genetic variants which may help predict the development of PNET in patients with hyperparathyroidism.
Interventions
- Other: Genome Sequencing
- Analyses includes genome sequencing based analysis to identify novel germline variations in blood DNAs and somatic changes in tumor DNAs, which may contribute to the development of pancreatic tumors.
- Other: Data Review
- Clinical information retrieved from the patients’ medical record including: de-identified demographic data (age, gender, race/ethnicity), medical history, family history, disease status, treatment response, survival information, and selected clinical data from medical record (calcium levels, calcitonin levels).
Arms, Groups and Cohorts
- Parathyroidectomy Tissue and Data
- Analyses includes genome sequencing based analysis to identify novel germline variations in blood DNAs and somatic changes in tumor DNAs, which may contribute to the development of pancreatic tumors. Clinical information retrieved from the patients’ medical record including: de-identified demographic data (age, gender, race/ethnicity), medical history, family history, disease status, treatment response, survival information, and selected clinical data from medical record (calcium levels, calcitonin levels).
Clinical Trial Outcome Measures
Primary Measures
- Identification of Somatic Mutations and Inherited Genetic Variants to Help Predict the Development of Pancreatic Neuroendocrine Tumors (PNET) in Participants with Hyperparathyroidism by Genome Sequencing
- Time Frame: 10 years
Secondary Measures
- Identification of Somatic Mutations and Inherited Genetic Variants to Help Predict the Development of Pancreatic Neuroendocrine Tumors (PNET) in Participants with Hyperparathyroidism by Data Review
- Time Frame: 10 years
Participating in This Clinical Trial
Inclusion Criteria
1. MEN1 patients who have undergone parathyroidectomy and did not develop PNET. 2. MEN1 patients who have undergone parathyroidectomy and had surgical removal of PNET. Exclusion Criteria:
N/A
Gender Eligibility: All
Minimum Age: N/A
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- M.D. Anderson Cancer Center
- Provider of Information About this Clinical Study
- Sponsor
- Overall Official(s)
- Nancy D. Perrier, MD, Principal Investigator, M.D. Anderson Cancer Center
- Overall Contact(s)
- Nancy D. Perrier, MD, 713-792-6940, NPerrier@mdanderson.org
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.